Live Breaking News & Updates on Kazia Therapeutics

Stay updated with breaking news from Kazia therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma. ....

Dana Farber Cancer Institute , United States , Tocilizumab Actemra , Lakshmi Nayak , Mono Pharmaceuticals , Wolters Kluwer Uptodate Inc , Harvard Medical School , Lymphoma At Dana Farber Cancer Institute , Kazia Therapeutics ,

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that,. ....

United States , New South Wales , Kazia Therapeutics Limited , Nasdaq Hearings Panel The , Kazia Therapeutics Limited The Company , Exchange Commission , Kazia Therapeutics , Prnewswire Kazia Therapeutics Limited , Therapeutics Limited , Minimum Bid Price Requirement , Minimum Bid Price , Listing Qualifications Staff , Nasdaq Stock Market , Nasdaq Listing Rule , Bid Price , Second Compliance Period , Nasdaq Capital Market , American Depositary Shares , Second Compliance , Nasdaq Hearings Panel , Orphan Drug Designation , Rare Pediatric Disease Designation , Annual Report , United States Securities ,

Head-To-Head Comparison: BioXcel Therapeutics (NASDAQ:BTAI) versus Kazia Therapeutics (NASDAQ:KZIA)

BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) and Kazia Therapeutics (NASDAQ:KZIA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations. Volatility and Risk BioXcel Therapeutics has a […] ....

New Haven , United States , New South Wales , Kazia Therapeutics , Bioxcel Therapeutics Inc , Bioxcel Therapeutics , Get Free Report , Xcel Therapeutics , Kazia Therapeutic , Given Bioxcel Therapeutic , Therapeutics Limited , Novogen Limited , Kazia Therapeutics Limited , Bioxcel Therapeutics Daily , Nasdaq Btai , Stock Comparison , Stock Analysis ,

Kazia Therapeutics (NASDAQ:KZIA) versus BioXcel Therapeutics (NASDAQ:BTAI) Head to Head Comparison

Kazia Therapeutics (NASDAQ:KZIA) versus BioXcel Therapeutics (NASDAQ:BTAI) Head to Head Comparison
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

New Haven , United States , New South Wales , Bioxcel Therapeutics Inc , Kazia Therapeutics , Get Free Report , Bioxcel Therapeutics , Bioxcel Therapeutic , Xcel Therapeutics , Given Bioxcel Therapeutic , Therapeutics Limited , Novogen Limited , Kazia Therapeutics Limited , Kazia Therapeutics Daily ,

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team. ....

United States , New South Wales , John Friend , Safety Review Team , Kazia Therapeutics Limited , Kazia Therapeutics , Exchange Commission , Prnewswire Kazia Therapeutics Limited , Therapeutics Limited , Orphan Drug Designation , Rare Pediatric Disease Designation , Annual Report , United States Securities ,